BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 27975104)

  • 1. Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction.
    Winter MP; Kleber ME; Koller L; Sulzgruber P; Scharnagl H; Delgado G; Goliasch G; März W; Niessner A
    Thromb Haemost; 2017 Feb; 117(3):471-478. PubMed ID: 27975104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction.
    Kleber ME; Koller L; Goliasch G; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; März W; Niessner A
    Circ Heart Fail; 2015 Jan; 8(1):25-32. PubMed ID: 25342739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
    Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
    Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction.
    Koller L; Kleber M; Goliasch G; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer T; Delgado G; Tomaschitz A; Pilz S; März W; Niessner A
    Eur J Heart Fail; 2014 Jul; 16(7):758-66. PubMed ID: 24806206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
    Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
    Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization.
    Nikolova AP; Hitzeman TC; Baum R; Caldaruse AM; Agvanian S; Xie Y; Geft DR; Chang DH; Moriguchi JD; Hage A; Azarbal B; Czer LS; Kittleson MM; Patel JK; Wu AHB; Kobashigawa JA; Hamilton M; Hong T; Shaw RM
    JAMA Cardiol; 2018 Dec; 3(12):1206-1210. PubMed ID: 30383171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
    Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
    Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
    Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
    Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease.
    Marcun R; Stankovic I; Vidakovic R; Farkas J; Kadivec S; Putnikovic B; Ilic I; Neskovic AN; Lainscak M
    Intern Emerg Med; 2016 Jun; 11(4):519-27. PubMed ID: 26423072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified Glasgow Prognostic Score is a novel predictor of clinical outcome in heart failure with preserved ejection fraction.
    Bolat I; Biteker M
    Scand Cardiovasc J; 2020 Jun; 54(3):174-178. PubMed ID: 31965867
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
    Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
    [No Abstract]   [Full Text] [Related]  

  • 19. Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction.
    Kanagala P; Arnold JR; Cheng ASH; Singh A; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
    Int J Cardiovasc Imaging; 2020 Jan; 36(1):101-110. PubMed ID: 31401742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
    JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.